Clinical Trial Update: A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB) [Phase 4]

View source ↗

Summary

Phase 4 trial comparing tolerability and patient preference between mirabegron and tolterodine ER in adults with overactive bladder has completed with posted re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Mirabegron (mirabegron)
• Tolterodine ER (tolterodine tartrate (extended-release))

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Overactive Bladder (OAB) | Phase 4 | Status: COMPLETED | Results posted: 2017-02-14